Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Breast Neoplasms 38Lung Neoplasms 29Carcinoma, Non-Small-Cell Lung 28Neoplasms 16Uterine Cervical Neoplasms 13Squamous Cell Carcinoma of Head and Neck 11Esophageal Neoplasms 10Carcinoma, Hepatocellular 10Sarcoma 9Rectal Neoplasms 9Carcinoma, Renal Cell 9Prostatic Neoplasms 8Neoplasm Metastasis 8Melanoma 8Lymphoma 8Glioblastoma 8Colorectal Neoplasms 8Brain Neoplasms 8Thyroid Neoplasms 7Stomach Neoplasms 7Solid Tumor 7Pancreatic Neoplasms 7Oropharyngeal Neoplasms 7Multiple Myeloma 7Head and Neck Neoplasms 7Colonic Neoplasms 7Urinary Bladder Neoplasms 6Lymphoma, Large B-Cell, Diffuse 6Hodgkin Disease 6Breast Neoplasms, Male 6

Interventions

lutetium Lu 177 dotatate 8lanreotide 4copper dotatate CU-64 4Octreotide 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4pasireotide 3Magnetic Resonance Spectroscopy 3Lutetium-177 3Lutetium 3gallium Ga 68 dotatate 2amino-acid, glucose, and electrolyte solution 2Temozolomide 2Nivolumab 2Irinotecan 2Ga(III)-DOTATOC 2Everolimus 2Etoposide 2Carboplatin 2zimberelimab 1regorafenib 1pembrolizumab 1irinotecan sucrosofate 1folfirinox 1famitinib 1cabozantinib 1arginyllysine 1abemaciclib 1X-Rays 1Sunitinib 1Somatostatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastro-enteropancreatic neuroendocrine tumor × Fluorodeoxyglucose F18 × Clear all
NCT05709171 2023-11-22

Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms

Rigshospitalet, Denmark

Phase 2 Unknown
200 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡